Vera Therapeutics (NASDAQ:VERA) Trading 6.5% Higher

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) rose 6.5% during trading on Wednesday . The stock traded as high as $42.39 and last traded at $42.09. Approximately 148,465 shares traded hands during trading, a decline of 88% from the average daily volume of 1,259,533 shares. The stock had previously closed at $39.51.

Wall Street Analysts Forecast Growth

VERA has been the topic of several analyst reports. Oppenheimer initiated coverage on shares of Vera Therapeutics in a research report on Thursday, January 25th. They set an “outperform” rating and a $26.00 price target on the stock. Raymond James raised Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $29.00 to $37.00 in a research report on Friday, January 26th. Cantor Fitzgerald assumed coverage on Vera Therapeutics in a research note on Monday, January 8th. They set an “overweight” rating on the stock. Wedbush upped their price target on Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a research note on Thursday, March 21st. Finally, Guggenheim restated a “buy” rating and set a $56.00 price target on shares of Vera Therapeutics in a research note on Friday, April 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Buy” and an average target price of $32.29.

Vera Therapeutics Stock Up 7.0 %

The business has a 50-day moving average price of $42.92 and a two-hundred day moving average price of $27.48. The company has a quick ratio of 7.71, a current ratio of 7.71 and a debt-to-equity ratio of 0.49. The firm has a market cap of $2.30 billion, a PE ratio of -17.95 and a beta of 1.05.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Wednesday, March 20th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.05). On average, equities research analysts expect that Vera Therapeutics, Inc. will post -2.18 EPS for the current year.

Insider Activity at Vera Therapeutics

In related news, Director Maha Katabi sold 81,009 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $44.20, for a total value of $3,580,597.80. Following the transaction, the director now owns 3,547,437 shares of the company’s stock, valued at $156,796,715.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Vera Therapeutics news, CFO Sean Grant sold 99,828 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total value of $3,954,187.08. Following the completion of the transaction, the chief financial officer now owns 66,337 shares in the company, valued at $2,627,608.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Maha Katabi sold 81,009 shares of the company’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $44.20, for a total transaction of $3,580,597.80. Following the completion of the transaction, the director now owns 3,547,437 shares of the company’s stock, valued at approximately $156,796,715.40. The disclosure for this sale can be found here. Insiders have sold 526,551 shares of company stock valued at $21,533,345 over the last quarter. 21.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Vera Therapeutics during the third quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Vera Therapeutics by 27.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,579 shares of the company’s stock worth $282,000 after buying an additional 4,387 shares during the period. Barclays PLC boosted its stake in shares of Vera Therapeutics by 964.6% during the third quarter. Barclays PLC now owns 71,703 shares of the company’s stock worth $983,000 after buying an additional 64,968 shares during the period. Amalgamated Bank boosted its stake in shares of Vera Therapeutics by 26.0% during the third quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock worth $57,000 after buying an additional 864 shares during the period. Finally, Swiss National Bank acquired a new stake in shares of Vera Therapeutics during the third quarter worth about $668,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.